Direct targeting of αvβ3 integrin on tumor cells with a monoclonal antibody, Abegrin™
| Autor: | Xiao Tao Yao, Bill Walsh, Michael S. Kinch, Krista Kinneer, Kathy Mulgrew, David A. Tice, Changshou Gao, Beth K. Ward, Peter A. Kiener, Steve Coats, Su Yau Mao, Melissa Damschroder |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Cancer Research
Angiogenesis medicine.drug_class Integrin Dose-Response Relationship Immunologic Mice Nude Mice SCID Antibodies Monoclonal Humanized Monoclonal antibody Flow cytometry Metastasis Mice Species Specificity Cell Line Tumor Neoplasms medicine Animals Humans Integrin alphaVbeta3 medicine.diagnostic_test biology Antibody-Dependent Cell Cytotoxicity Antibodies Monoclonal medicine.disease Xenograft Model Antitumor Assays Molecular biology Oncology Cell culture Monoclonal Cancer research biology.protein Female |
| Zdroj: | Molecular Cancer Therapeutics. 5:3122-3129 |
| ISSN: | 1538-8514 1535-7163 |
| Popis: | The humanized monoclonal antibody Abegrin™, currently in phase II trials for treatment of solid tumors, specifically recognizes the integrin αvβ3. Due to its high expression on mature osteoclasts, angiogenic endothelial cells, and tumor cells, integrin αvβ3 functions in several pathologic processes important to tumor growth and metastasis. Targeting of this integrin with Abegrin™ results in antitumor, antiangiogenic, and antiosteolytic activities. Here, we exploit the species specificity of Abegrin™ to evaluate the effects of direct targeting of tumor cells (independent of targeting of endothelia or osteoclasts). Flow cytometry analysis of human tumor cell lines shows high levels of αvβ3 on many solid tumors, including cancers of the prostate, skin, ovary, kidney, lung, and breast. We also show that tumor growth of αvβ3-expressing tumor cells is inhibited by Abegrin™ in a dose-dependent manner. We present a novel finding that high-dose administration can actively impair the antitumor activity of Abegrin™. We also provide evidence that antibody-dependent cellular cytotoxicity contributes to in vitro and in vivo antitumor activity. Finally, it was observed that peak biological activity of Abegrin™ arises at serum levels that are consistent with those achieved in clinical trials. These results support a concept that Abegrin™ can be used to achieve selective targeting of the many tumor cells that express αvβ3 integrin. In combination with the well-established concept that αvβ3 plays a key role in cancer-associated angiogenesis and osteolytic activities, this triad of activity could provide new opportunities for therapeutic targeting of cancer. [Mol Cancer Ther 2006;5(12):3122–9] |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|